Veraxa Biotech Holding AG (VRXA) Max Pain Analysis
Max pain is the strike price where aggregate option buyer payout is minimized at expiration. It represents the price at which option writers retain the most premium.
Veraxa Biotech Holding AG (VRXA) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $299.8M, listed on NASDAQ, employing roughly 8 people, carrying a beta of 0.25 to the broader market. Veraxa Biotech Holding AG is a clinical-stage biopharmaceutical company, formed via a merger with Voyager Acquisition Corp. Led by Christoph Antz, public since 2026-06-09.
Max pain analysis shows the strike price where the most options expire worthless. No recent options activity for VRXA as of 2026-07-17; this typically reflects low options liquidity, a recently listed name, or a temporary data feed delay. Snapshot will refresh on the next active session.